Key Points
- Labcorp CEO Adam Schechter sold 4,669 shares for approximately $1.50 million under a pre-arranged Rule 10b5-1 trading plan, reducing his ownership by 4.35% to 102,565 shares.
- Labcorp reported quarterly EPS of $4.99, exceeding estimates of $4.78, while revenue rose 5.8% year over year to $3.73 billion. The company guided for fiscal 2026 EPS of $18.10–$18.55.
- Analysts maintain a generally positive view, with nine Buy ratings and three Holds, an average “Moderate Buy” rating, and a $330 average price target. Labcorp also declared a quarterly dividend of $0.72 per share, yielding about 0.9%.
Labcorp Holdings Inc. (NYSE:LH - Get Free Report) CEO Adam Schechter sold 4,669 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the transaction, the chief executive officer owned 102,565 shares in the company, valued at approximately $32,858,749.05. This trade represents a 4.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Labcorp Stock Performance
Shares of Labcorp stock opened at $322.90 on Thursday. The firm's fifty day simple moving average is $283.96 and its 200-day simple moving average is $273.97. The stock has a market capitalization of $26.19 billion, a price-to-earnings ratio of 26.71, a PEG ratio of 1.87 and a beta of 0.87. Labcorp Holdings Inc. has a 12 month low of $244.52 and a 12 month high of $323.97. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.80 and a quick ratio of 1.53.
Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, beating the consensus estimate of $4.78 by $0.21. The firm had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. Labcorp's revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $4.35 EPS. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, equities analysts forecast that Labcorp Holdings Inc. will post 18.32 earnings per share for the current year.
Labcorp Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 28th. Labcorp's dividend payout ratio is presently 23.82%.
Analyst Ratings Changes
A number of equities analysts recently issued reports on LH shares. Weiss Ratings raised Labcorp from a "buy (b-)" rating to a "buy (b)" rating in a report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $306.00 price objective on shares of Labcorp in a research note on Friday, July 31st. Morgan Stanley increased their price objective on Labcorp from $308.00 to $338.00 and gave the stock an "overweight" rating in a research report on Friday, July 31st. JPMorgan Chase & Co. lifted their target price on Labcorp from $330.00 to $360.00 and gave the company an "overweight" rating in a research note on Monday, August 3rd. Finally, Bank of America boosted their target price on Labcorp from $300.00 to $320.00 and gave the company a "buy" rating in a report on Monday, July 13th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $330.00.
Get Our Latest Analysis on Labcorp
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Labcorp by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 9,850,631 shares of the medical research company's stock worth $2,471,326,000 after buying an additional 37,197 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Labcorp by 103.1% in the fourth quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company's stock valued at $1,343,922,000 after buying an additional 2,719,475 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in Labcorp by 1.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company's stock valued at $607,241,000 after buying an additional 22,170 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Labcorp by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company's stock valued at $534,023,000 after acquiring an additional 13,775 shares during the period. Finally, Wellington Management Group LLP lifted its position in shares of Labcorp by 15.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company's stock valued at $604,488,000 after acquiring an additional 289,029 shares during the period. Hedge funds and other institutional investors own 95.94% of the company's stock.
About Labcorp
(
Get Free Report)
Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.
Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
